Suppr超能文献

新冠病毒 S 蛋白受体结合域的种内与种间进化:非关联选择驱动下的进化受阻

Intra- vs. Interhost Evolution of SARS-CoV-2 Driven by Uncorrelated Selection-The Evolution Thwarted.

机构信息

State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.

Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

出版信息

Mol Biol Evol. 2023 Sep 1;40(9). doi: 10.1093/molbev/msad204.

Abstract

In viral evolution, a new mutation has to proliferate within the host (Stage I) in order to be transmitted and then compete in the host population (Stage II). We now analyze the intrahost single nucleotide variants (iSNVs) in a set of 79 SARS-CoV-2 infected patients with most transmissions tracked. Here, every mutation has two measures: 1) iSNV frequency within each individual host in Stage I; 2) occurrence among individuals ranging from 1 (private), 2-78 (public), to 79 (global) occurrences in Stage II. In Stage I, a small fraction of nonsynonymous iSNVs are sufficiently advantageous to rise to a high frequency, often 100%. However, such iSNVs usually fail to become public mutations. Thus, the selective forces in the two stages of evolution are uncorrelated and, possibly, antagonistic. For that reason, successful mutants, including many variants of concern, have to avoid being eliminated in Stage I when they first emerge. As a result, they may not have the transmission advantage to outcompete the dominant strains and, hence, are rare in the host population. Few of them could manage to slowly accumulate advantageous mutations to compete in Stage II. When they do, they would appear suddenly as in each of the six successive waves of SARS-CoV-2 strains. In conclusion, Stage I evolution, the gate-keeper, may contravene the long-term viral evolution and should be heeded in viral studies.

摘要

在病毒进化中,新的突变必须在宿主(第一阶段)中增殖,以便传播,然后在宿主群体中竞争(第二阶段)。我们现在分析了一组 79 名 SARS-CoV-2 感染患者的宿主内单核苷酸变异(iSNV),其中大多数传播都得到了跟踪。在这里,每个突变都有两个衡量标准:1)每个个体宿主在第一阶段的 iSNV 频率;2)个体之间的发生情况,从 1(私有)到 78(公共),再到第二阶段的 79(全球)。在第一阶段,少数非同义 iSNV 具有足够的优势,频率上升到很高的水平,通常为 100%。然而,这些 iSNV 通常无法成为公共突变。因此,进化的两个阶段的选择力是不相关的,可能是拮抗的。因此,成功的突变体,包括许多关注的变体,必须在首次出现时避免在第一阶段被淘汰。因此,它们可能没有传播优势来与优势菌株竞争,因此在宿主群体中很少见。其中一些可能会设法缓慢积累有利的突变,以在第二阶段竞争。当它们这样做时,它们会突然出现,就像 SARS-CoV-2 连续六波的每一波一样。总之,第一阶段的进化,即守门员,可能与病毒的长期进化相悖,在病毒研究中应予以重视。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cf8/10521905/8b62d34e3bab/msad204f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验